New drug shows promise in controlling debilitating lupus symptoms

NCT ID NCT04931563

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study tested whether a drug called anifrolumab could better control active systemic lupus erythematosus (lupus) in Asian adults compared to a placebo. All 277 participants continued their standard lupus medications and received either the new drug or a placebo via IV every 4 weeks for a year. The main goal was to see if the new treatment reduced lupus disease activity more effectively.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Baoding, 071000, China
Research Site

Baotou, 014010, China
Research Site

Beijing, 100029, China
Research Site

Beijing, 100034, China
Research Site

Beijing, 100144, China
Research Site

Beijing, 100191, China
Research Site

Beijing, 100730, China
Research Site

Bengbu, 233004, China
Research Site

Binzhou, 256603, China
Research Site

Changchun, China
Research Site

Changsha, 410008, China
Research Site

Chuangchun, 130012, China
Research Site

Guangzhou, 510080, China
Research Site

Guangzhou, 510260, China
Research Site

Guilin, 541001, China
Research Site

Hangzhou, 310006, China
Research Site

Hengyang, 421001, China
Research Site

Jieyang, 522000, China
Research Site

Jinan, 250012, China
Research Site

Jining, 272011, China
Research Site

Kunming, 650032, China
Research Site

Lanzhou, 730000, China
Research Site

Linyi, 276003, China
Research Site

Luoyang, 471003, China
Research Site

Nanchang, 330006, China
Research Site

Nanchong, 637000, China
Research Site

Nanjing, 210008, China
Research Site

Nanyang, 473005, China
Research Site

Shanghai, 200025, China
Research Site

Shengyang, 110004, China
Research Site

Shenyang, 110001, China
Research Site

Shenzhen, 518020, China
Research Site

Shijiazhuang, 050001, China
Research Site

Suzhou, 215006, China
Research Site

Tianjin, 300050, China
Research Site

Ürümqi, 831118, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430030, China
Research Site

Wuxi, 214002, China
Research Site

Xiamen, 361003, China
Research Site

Xinxiang, 453002, China
Research Site

Yinchuan, 750004, China
Research Site

Zaozhuang, 277102, China
Research Site

Zhengzhou, 450052, China
Research Site

Hong Kong, 00000, Hong Kong
Research Site

Hong Kong, Hong Kong
Research Site

Davao City, PH-8000, Philippines
Research Site

Iloilo City, 5000, Philippines
Research Site

Lipa City, 4217, Philippines
Research Site

Manila, 1000, Philippines
Research Site

Quezon City, 1112, Philippines
Research Site

Gwangju, 501-757, South Korea
Research Site

Seoul, 04763, South Korea
Research Site

Seoul, 6591, South Korea
Research Site

Suwon, 16499, South Korea
Research Site

Kaohsiung City, 81362, Taiwan
Research Site

New Taipei City, 220, Taiwan
Research Site

New Taipei City, 23561, Taiwan
Research Site

Taichung, 40447, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Taipei, 11220, Taiwan
Research Site

Taipei, 114, Taiwan
Research Site

Taoyuan District, 333, Taiwan
Research Site

Bangkok, 10400, Thailand

Conditions

Explore the condition pages connected to this study.

ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS